SS-31 Peptide: Research Outcomes and What Studies Report

What Is SS-31?

SS-31 is a synthetic mitochondria-targeting tetrapeptide, also known by its clinical alias elamipretide and the earlier research name Bendavia, designed to concentrate at the inner mitochondrial membrane and stabilize cardiolipin — a phospholipid critical to mitochondrial energy production. The compound's alternating aromatic and cationic amino acids allow it to cross lipid bilayers and accumulate selectively in mitochondria, distinguishing it mechanistically from general antioxidants. Research spanning 2019 to 2026 has examined SS-31 across a range of conditions tied to mitochondrial dysfunction, from rare genetic cardiomyopathy to acute organ injury and skeletal muscle impairment.

---

What Is SS-31 Studied For?

Research on SS-31 goes back to 2019 — 7 years — with studies continuing through 2026.

1. Cardiolipin Stabilization in Genetic Cardiomyopathy — A phase 2/3 randomized, double-blind, placebo-controlled crossover trial enrolling 12 participants with Barth syndrome, a genetic disorder of cardiolipin metabolism, reported improvements in exercise tolerance and skeletal muscle function following elamipretide treatment.

2. Skeletal Muscle Performance in Heart Failure — A 2026 preclinical study using a rat model of heart failure with preserved ejection fraction (n=10) found that elamipretide improved skeletal muscle contractile performance, attributing the effect to restored cardiolipin integrity and mitochondrial function.

3. Acute Kidney Injury Protection — A mouse study (32 C57BL/6 mice) reported that SS-31 attenuated cisplatin-induced acute kidney injury by modulating a mitochondrial reactive oxygen species pathway linked to inflammasome activation.

4. Sensory Hair Cell Preservation — A 2019 zebrafish study reported that pretreatment with Bendavia produced dose-dependent protection of lateral line hair cells against gentamicin-induced damage, a model relevant to aminoglycoside ototoxicity research.

5. Neuroprotection Against Toxic Injury — A 2025 rat study examining methanol poisoning found that elamipretide reduced histopathological and biochemical markers of damage in the optic nerve, retina, and brain tissue.

---

How Does SS-31 Work?

SS-31 acts at the inner mitochondrial membrane, where cardiolipin is most concentrated. Cardiolipin organizes the electron transport chain complexes into functional supercomplexes; when it is damaged or oxidized, electron transport efficiency drops and reactive oxygen species output increases. A 2022 rodent study on aging and high-sugar diet found that SS-31 treatment was associated with attenuation of cardiac hypertrophy and preserved mitochondrial function in aged mice, consistent with a cardiolipin-stabilizing mechanism rather than a direct antioxidant scavenging effect.

The compound also intersects with mitophagy — the selective removal of damaged mitochondria. A 2026 rat and cell-based preclinical study on trauma-induced tendon heterotopic ossification found that SS-31 modulated the PINK1/Parkin mitophagy pathway through targeting ANT1, reducing aberrant osteogenic differentiation in tendon progenitor cells. This positions SS-31 not only as a membrane stabilizer but as a regulator of mitochondrial quality-control signaling.

---

What Does Animal Research on SS-31 Report?

The majority of the SS-31 evidence base comes from rodent and zebrafish preclinical models, covering a wide range of organ systems.

In the kidney, a mouse study using 32 C57BL/6 animals divided into four groups — control, cisplatin, cisplatin with saline, and cisplatin with SS-31 — reported that SS-31 administration reduced markers of oxidative stress and suppressed NLRP3 inflammasome activation, a pathway implicated in acute kidney injury progression. The cisplatin model is a well-established proxy for drug-induced nephrotoxicity research.

In the heart, a 2026 rat preclinical study (n=10) using a HFpEF model found that elamipretide improved skeletal muscle contractile force and mitochondrial respiration capacity, with the authors attributing effects to restored cardiolipin structure in muscle mitochondria. A separate 2022 rodent aging study reported that aged mice on a high-sucrose diet developed accelerated cardiac hypertrophy with pronounced mitochondrial impairment, and that SS-31 treatment attenuated structural remodeling in that context.

In the inner ear, a 2019 zebrafish study used the lateral line hair cell system — a model widely used for ototoxicity screening — and found that pretreatment with Bendavia reduced gentamicin-induced hair cell loss in a dose-dependent manner. The authors linked the protection to mitochondrial preservation rather than direct drug efflux.

For ocular and neurological tissue, a 2025 rat study (40 male Wistar Albino rats, six groups) examined methanol poisoning, which induces oxidative injury across the retina, optic nerve, and brain. Elamipretide-treated animals showed reduced biochemical markers of oxidative damage and less histopathological disruption compared to untreated poisoned controls.

In the musculoskeletal domain, a 2026 preclinical study on trauma-induced tendon heterotopic ossification — using both rat models and cell-based assays — reported that SS-31 reduced ectopic bone formation by activating PINK1/Parkin-mediated mitophagy via ANT1 targeting, decreasing the osteogenic potential of tendon stem/progenitor cells.

One in vitro and in vivo study also investigated elamipretide in a reproductive biology context: a 2022 bull sperm cryopreservation study (n=36 ejaculates) found that adding elamipretide to freezing media improved post-thaw sperm motility and reduced oxidative stress markers, consistent with the compound's mitochondrial membrane-protective profile.

---

What Does Human Research on SS-31 Report?

Human trial data on SS-31 is currently concentrated in a single rare disease indication. A phase 2/3 randomized, double-blind, placebo-controlled crossover trial followed by an open-label extension evaluated elamipretide in Barth syndrome — a rare X-linked genetic disorder in which TAZ gene mutations produce abnormal cardiolipin on the inner mitochondrial membrane, causing cardiomyopathy, skeletal myopathy, and exercise intolerance. The trial enrolled 12 participants.

The study reported that elamipretide treatment was associated with improvements in the 6-minute walk test and measures of skeletal muscle strength relative to placebo. The open-label extension phase provided additional durability data. The authors noted that the mechanism of action — direct cardiolipin interaction — aligns precisely with the metabolic defect in Barth syndrome, making this population a high-face-validity test of the compound's proposed biology.

Several important limitations apply when interpreting this trial. The sample size of 12 reflects the rarity of Barth syndrome rather than a study design shortcoming, but it constrains statistical power and generalizability. All participants were male and relatively young, consistent with the X-linked inheritance pattern of the disease. Whether the results extend to more common forms of mitochondrial dysfunction in older or more heterogeneous populations remains an open question not addressed by current human data.

No large-scale phase III trial results appear in the current study pool, and human evidence beyond the Barth syndrome setting has not yet been published in peer-reviewed form among the studies available for this review.

---

What Is Still Unknown About SS-31?

The gap between the animal evidence base and human trial data is substantial. Preclinical studies span kidney injury, cardiac remodeling, ototoxicity, neurological protection, tendon pathology, and reproductive biology — yet the only published human randomized trial covers a single ultra-rare genetic disease with 12 participants. Whether SS-31's mitochondrial mechanisms translate to more prevalent conditions such as ischemia-reperfusion injury, age-related hearing loss, or common forms of heart failure remains unresolved at the human level.

Dose-response relationships in humans are not characterized by the current evidence pool. The animal studies use a range of administration routes and experimental contexts that do not map cleanly to human pharmacokinetics. Long-term safety data from human populations is similarly limited; the open-label extension of the Barth syndrome trial offers some durability information, but the n=12 ceiling applies there as well.

The 2026 HFpEF rat study represents an active research direction — skeletal muscle dysfunction in heart failure is a high-prevalence clinical problem — but that work has not yet produced human trial data. The tendon heterotopic ossification findings and the optic nerve protection data are at early preclinical stages. Research in these areas is ongoing, and the coming years are likely to determine whether the breadth of the animal signal narrows or expands when tested in human participants.

---

Where Can I Buy SS-31?

SS-31 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---